Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions

Acquired BRAF V600E mutation can occur in tumors with EGFR mutation and is suspected as a resistance mechanism to third‐generation EGFR‐tyrosine kinase inhibitors (TKIs). However, the treatment strategy for the coexistence of EGFR and acquired BRAF mutation with heterogeneity in lung cancer has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Mengyao, Wang, Xu, Xu, Yinghui, Sun, Chao, Guo, Ye, Qiu, Shi, Zhao, Renshan, Zhu, Wenhao, Ma, Kewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807254/
https://www.ncbi.nlm.nih.gov/pubmed/34962076
http://dx.doi.org/10.1111/1759-7714.14295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807254/
https://www.ncbi.nlm.nih.gov/pubmed/34962076
http://dx.doi.org/10.1111/1759-7714.14295

Ejemplares similares